CAS · 58-32-2
Product Overview
Dypyridamole is a high-purity a-api supplied for industrial and specialty chemical applications. Contact our team for specifications, packaging options and lead times.
Product Specifications
| Grade | EP11.0 |
|---|---|
| Appearance | Bright yellow, crystalline powder |
| Assay (on dry basis) | 98.5 ~ 101.5% |
| Solubility | Practically insoluble in water, freely soluble in acetone, soluble in anhydrous ethanol, freely soluble in diluted hydrochloric acid |
| Identification | IR |
| Sulfated ash | 0.1% max |
| Impurity A | 0.5% max |
| Impurity B | 0.5% max |
| Impurity C | 0.5% max |
| Impurity D | 0.2% max |
| Impurity E | 0.2% max |
| Any other unknown impurity | 0.1% max |
| Total impurities | 1.0% max |
| Methanol (Residual solvent) | 0.2% max |
| Ethanol (Residual solvent) | 0.2% max |
| Benzenesulfonate esters | 3.75 ppm max |
| Chlorides | 200 ppm max |
| Loss on drying | 0.5% max |
Applications
Dypyridamole is a pharmaceutical compound widely used in cardiovascular research, clinical therapy, and drug development. It is primarily applied as a platelet aggregation inhibitor, supporting the prevention of thromboembolic events such as stroke and myocardial infarction. In clinical research, dypyridamole is used in combination therapies to enhance antiplatelet effects and improve blood flow in patients with cardiovascular disorders. It also serves as a vasodilator in diagnostic procedures, including myocardial perfusion imaging and stress testing, where it aids in assessing coronary artery function. In pharmaceutical research, dypyridamole is utilized as a reference compound for evaluating new antithrombotic agents, exploring mechanisms of platelet inhibition, and studying drug interactions with cyclic nucleotide pathways.
Benefits
The benefits of dypyridamole are closely associated with its multifunctional pharmacological profile, safety, and therapeutic efficacy. It inhibits platelet aggregation by increasing intracellular cyclic AMP and reducing thromboxane production, providing a protective effect against blood clot formation. Its vasodilatory action enhances microcirculation, improving tissue perfusion during diagnostic procedures and therapeutic applications. Dypyridamole demonstrates good oral bioavailability, manageable pharmacokinetics, and compatibility with other cardiovascular medications, making it suitable for combination therapy. Its well-characterized mechanism of action and established clinical history provide reliability in both research and therapeutic contexts, supporting reproducible and predictable outcomes.
Conclusion
Dypyridamole is a versatile cardiovascular agent with broad applications in thrombosis prevention, vasodilation, and pharmaceutical research. Its dual role as a platelet inhibitor and vasodilator, combined with proven efficacy and safety, makes it an essential compound in clinical therapy and drug development. By enabling improved blood flow, preventing thromboembolic events, and supporting cardiovascular research, dypyridamole continues to play a critical role in modern medicine and biomedical studies.
Previous
Kanamycin Sulfate丨CAS 25389-94-0
Next